Evaluation of cumulative prognostic score based on pretreatment plasma fibrinogen and serum albumin levels in patients with newly diagnosed high-grade gliomas

He, Zhen Qiang; Duan, Hao; Ke, Chao; Zhang, Xiang Heng; Guo, Cheng; Al-Nahari, Fuad; Zhang, Ji; Chen, Zheng He; Chen, Yin Sheng; Liu, Zhi Gang; Wang, Jian; Chen, Zhongping; Jiang, Xiao Bing; Mou, Yong

doi:10.18632/oncotarget.17849

Cited by 22 publications

(23 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fibrinogen was shown to play important roles both in tumor cell proliferation, migration and angiogenesis and as regulator of inflammation in solid tumors. They conclude that higher pretreatment FA score was an independent prognostic factor of PFS and OS of patients with high-grade gliomas and was significantly associated with advanced age and higher tumor grade [86].…”

Section: Biomarkers Related To Nutritional Statusmentioning

confidence: 96%

Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance?

Linhares

Carvalho

Vaz

et al. 2020

IJMS

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most frequent malignant primary brain tumor in adults, characterized by a highly aggressive, inflammatory and angiogenic phenotype. It is a remarkably heterogeneous tumor at several levels, including histopathologically, radiographically and genetically. The 2016 update of the WHO Classification of Tumours of the Central Nervous System highlighted molecular parameters as paramount features for the diagnosis, namely IDH1/2 mutations that distinguish primary and secondary GBM. An ideal biomarker is a molecule that can be detected/quantified through simple non- or minimally invasive methods with the potential to assess cancer risk; promote early diagnosis; increase grading accuracy; and monitor disease evolution and treatment response, as well as fundamentally being restricted to one aspect. Blood-based biomarkers are particularly attractive due to their easy access and have been widely used for various cancer types. A number of serum biomarkers with multiple utilities for glioma have been reported that could classify glioma grades more precisely and provide prognostic value among these patients. At present, screening for gliomas has no clinical relevance. This is because of the low incidence, the lack of sensitive biomarkers in plasma, and the observation that gliomas may develop apparently de novo within few weeks or months. To the best of our knowledge, there is no routine use of a serum biomarker for clinical follow-up. The purpose of this paper is to review the serum biomarkers described in the literature related to glioblastoma and their possible relationship with clinical features.

show abstract

Section: Biomarkers Related To Nutritional Statusmentioning

confidence: 96%

Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance?

Linhares

Carvalho

Vaz

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…There were numerous studies suggested that high plasma fibrinogen levels were associated with worse clinical outcome in a variety of solid tumors 6 . The prognostic value of plasma fibrinogen was also proven in human gliomas 7 , 8 . Nevertheless, the reliability and degree of this prognostic marker needed to be re-evaluated, due to limited cases and variation in study designs.…”

Section: Introductionmentioning

confidence: 95%

Higher Plasma Fibrinogen Levels are Associated with Malignant Phenotype and Worse Survival in Patients with Glioblastomas

Wang¹,

Meng²,

Song³

et al. 2018

J. Cancer

View full text Add to dashboard Cite

Preoperative plasma fibrinogen levels were associated with poor clinical outcomes in malignancies. There were few data about the prognostic value of plasma fibrinogen in glioblastomas (GBMs). The objective of our study was to investigate the association between fibrinogen and patients' clinicopathological factors and overall survival (OS). From 2008 to 2016, 315 patients with GBMs who had a surgical treatment at our institute, were retrospectively involved in this study. IDH (isocitrate dehydrogenase) mutations and ATRX (alpha thalassemia/mental retardation syndrome X-linked) loss were detected with IHC (Immunohistochemistry). The preoperative plasma fibrinogen levels ranged from 1.00 to 5.22 g/L, with a mean of were 2.57 g/L. There were increased levels of plasma fibrinogen in patients aged ≥ 65 years, secondary GBMs, IDH mutation (p = 0.033) and ATRX loss (p = 0.040). Moreover, the plasma fibrinogen level was the highest in the subtype of IDH-1R132H wildtype - ATRX expression, which showed a shorter OS compared to the group of IDH-1R132H mut and IDH-1R132H wildtype - ATRX loss (p = 0.001, log-rank test). ROC curves for fibrinogen and IDH-1R132H wildtype - ATRX expression was also plotted, and indicated a potential diagnostic value of fibrinogen in molecular pathology. Univariate analysis found that younger age, higher KPS (Karnofsky Performance Score), gross total resection, complete chemoradiotherapy, IDH-1R132H mutations and lower levels of fibrinogen were associated with favorable outcomes. Multivariate analysis proved that chemoradiotherapy, IDH-1R132H and fibrinogen were independent prognostic factors. In conclusion, plasma fibrinogen could predict clinical outcome and molecular subtype in GBMs.

show abstract

“…The Glasgow Prognostic Score (GPS), which combines serum CRP with albuminemia and has been demonstrated to be a predictive factor in various cancers, is regarded as a prognostic milestone among all the systems (Forrest, McMillan, & McArdle, ; McMillan, ). Other prognostic systems such as neutrophil to lymphocyte ratio (NLR) (Cho et al, ; McNamara et al, ; Tajiri et al, ), platelet to lymphocyte ratio (PLR) (Kwon, Kim, & Oh, ; Li et al, ), and fibrinogen (He et al, ; Luo, Kim, Kim, Lee, & Song, ; Seebacher et al, ), can help predict the progression, metastasis, and prognosis of cancer patients.…”

Section: Introductionmentioning

confidence: 99%

The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F‐NLR) is a predictive factor in patients with resectable non small cell lung cancer

Wang

Zhao

Zhang

et al. 2017

Journal Cellular Physiology

View full text Add to dashboard Cite

The prognostic value of inflammation indexes in non small cell lung cancer (NSCLC) was not established. Therefore, we assessed the clinical applicability of the F-NLR score, which is based on fibrinogen (F) and the neutrophil-lymphocyte ratio (NLR), and the glasgow prognostic score (GPS) to predict the prognoses of NSCLC patients. We retrospectively identified 515 patients with stage I/II/IIIA who underwent surgery at our institution, and evaluated their preoperative serum levels of CRP, albumin, fibrinogen, neutrophil count, and the lymphocyte count. The cut-off values of the fibrinogen level and NLR were determined with receiver operating characteristic (ROC) curve. GPS was classified into three groups as previously described. The disease free survival (DFS) and overall survival (OS) were calculated by the Kaplan-Meier method. Categorical variables were compared using the χ test. Survival curves were estimated using the Kaplan-Meier method, and the Cox proportional hazard model was used to assess the prognostic factors. The F-NLR was significantly associated with sex (p = 0.000), smoking history (p = 0.014), lesion type (p = 0.000), histologic type (p = 0.000), T stage (p = 0.000), venous invasion (p = 0.000), lymphatic invasion (p = 0.000), and TNM stage (p = 0.000). The 5-year DFS rates in F-NLR groups 0, 1, and 2 were 46.7%, 36.4%, 30.1%, respectively (p = 0.000), and the 5-year overall survival (OS) rates in the above three groups were 52.0%, 39.8%, 32.1%, respectively (p = 0.000). Multivariate analysis showed that venous invasion (p = 0.036), lymph node metastasis (p = 0.000), and F-NLR (p = 0.034) were independent prognostic factors for DFS. Age (p = 0.015), venous invasion (p = 0.024), lymph node metastasis (p = 0.000), and F-NLR (p = 0.019) were independent prognostic factors for OS. Thus, F-NLR was the independent prognostic factor for both the DFS and OS. And patients with a high-risk preoperative F-NLR group may benefit from adjuvant therapy by subgroup analysis. Our results demonstrated that F-NLR, a novel inflammation-based grading system, as well as the GPS, appeared to have value as a promising clinical predictor of the prognosis for the resectable non small cell lung cancer patients.

show abstract

Evaluation of cumulative prognostic score based on pretreatment plasma fibrinogen and serum albumin levels in patients with newly diagnosed high-grade gliomas

Cited by 22 publications

References 35 publications

Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance?

Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance?

Higher Plasma Fibrinogen Levels are Associated with Malignant Phenotype and Worse Survival in Patients with Glioblastomas

The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F‐NLR) is a predictive factor in patients with resectable non small cell lung cancer

Contact Info

Product

Resources

About